1 Min Read
Jan 8 (Reuters) - Aptevo Therapeutics Inc:
* APTEVO THERAPEUTICS BEGINS PATIENT DOSING IN PHASE 2 CLINICAL TRIAL OF OTLERTUZUMAB IN PERIPHERAL T-CELL LYMPHOMA Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.